Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Mega Genomics Limited
美因基因有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6667)

INSIDE INFORMATION
DELAY IN PUBLICATION OF 2025 INTERIM REPORT
QUARTERLY UPDATE ON RESUMPTION PROGRESS
AND
CONTINUED SUSPENSION OF TRADING

This announcement is made by Mega Genomics Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 1 April 2025, 22 April 2025, 30 April 2025, 5 May 2025, 30 May 2025 and 29 August 2025 (the "**Announcements**") in relation to, among other matters, (i) delay in publication of the 2024 Annual Results and 2025 Interim Results, (ii) postponement of the Board meeting, (iii) delay in publication of the 2024 Annual Report, (iv) proposed change of the auditor; and (v) resumption guidance from the Stock Exchange. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Announcements.

DELAY IN DESPATCH OF 2025 INTERIM REPORT

Pursuant to Rules 13.48(1) of the Listing Rules, the Company is required to despatch its interim report for the six months ended 30 June 2025 (the "**2025 Interim Report**") to its shareholders not later than three months after the date upon which the financial period ended, that is, on or before 30 September 2025.

Due to the matters set out in the Announcements, the publication of the 2024 Annual Results and despatch of the 2024 Annual Report are still pending as of the date of this announcement. The despatch of the 2025 Interim Report is therefore expected to be delayed within the prescribed time in accordance with the Listing Rules.

QUARTERLY UPDATE ON RESUMPTION PROGRESS

The Company also wishes to inform its Shareholders and potential investors of the progress of actions recently taken by the Company in connection with fulfilling the Resumption Guidance and the latest development of the Group's business operations.

Update of Business Operations

The Group is a leading genetic testing platform company in China, principally engaged in providing customers with consumer genetic testing services and cancer screening services. Since the suspension of trading in the shares of the Company and up to the date of this announcement, the Group has been carrying on its business operations as usual in all material. As of 30 June 2025, the Group has collaborated with healthcare institutions in over 340 cities across China, and has performed over 24 million genetic tests in total.

Independent Investigation

As disclosed in the Company's announcement dated 22 April 2025, the Board has resolved to establish the Investigation Committee. As at the date of this announcement, the Company has engaged an independent investigation company to commence an independent investigation. The Company has been actively assisting the independent investigation company in the course of investigation under the overall supervision of the Investigation Committee. The preliminary draft of the independent investigation report has been completed and submitted to the Stock Exchange for review. The Company will make further announcement(s) to update the Shareholders and potential investors on the latest progress of the independent investigation as and when necessary.

Internal Control Review

The Company has engaged an external independent adviser for an internal control review to assess the effectiveness and efficiency of the Group's internal control environment and to provide the Company with recommendations for improvement and/or remedies, so as to address the weakness and deficiencies (if any) in the internal control system identified in the internal control review. As at the date of this announcement, the Company is working with the external independent adviser to prepare the internal control report and will disclose the results of the internal control report as soon as practicable.

Resumption Plan

In order to satisfy the Resumption Guidance, the Company is working with its professional advisers on formulating the resumption plan, which contains the actions it intends to take to address the matters that have led to its suspension of trading and to satisfy the Resumption Guidance, and continues to endeavor to satisfy the requirements of the Resumption Guidance. The Company will seek to resume trading in its shares on the Stock Exchange as soon as possible. Further announcement(s) will be made by the Company to update the Shareholders and the public on, among other things, the progress of the resumption plan of the Company as and when appropriate.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2025 and will remain suspended until further notice. Further announcement(s) will be made by the Company as and when appropriate and in accordance with the Listing Rules.

Shareholders and prospective investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mega Genomics Limited
LIN Lin
Executive Director and Chairperson

Hong Kong, 30 September 2025

As of the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.

* *For identification purpose only*